Menkes disease is a X-linked recessive disorder of brain copper metabolism caused by mutations in an essential mammalian copper transporter gene, ATP7A, affecting approximately 200 to 400 individuals in the United States. Copper replacement therapy has been used to treat Menkes disease. The present disclosure shows that treatment of Menkes disease. The present disclosure shows that treatment of Menkes disease patients with copper histidinate increases survival of the patients.

Menkes disease is a X-linked recessive disorder of brain copper metabolism caused by mutations in an essential mammalian copper transporter gene, ATP7A, affecting approximately 200 to 400 individuals in the United States. Copper replacement therapy has been used to treat Menkes disease. The present disclosure shows that treatment of Menkes disease. The present disclosure shows that treatment of Menkes disease patients with copper histidinate increases survival of the patients.

The invention relates to an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.

Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.

Nutritional compositions with fucosyllactose and betagalactooligosaccharides for use in stimulation of the immune system. The composition is suitable for infants.

The present invention relates to a method of reducing or preventing the symptoms associated with the intake of alcohol. The method comprises administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a H.sub.1-antihistamine.

A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.

Provided herein are antioxidant-enriched multivitamin compositions comprising vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folic acid, vitamin B 12, biotin, pantothenic acid, zinc, selenium, coenzyme Q10, lutein, lycopene, and zeaxanthin for the treatment of fat malabsorption diseases such as cystic fibrosis. Also provided are methods of treating vitamin and micronutrient deficiencies in subjects suffering from cystic fibrosis by administering an antioxidant-enriched multivitamin composition.

The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimes saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.

Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.